Targeting NMDA Receptor Complex in Management of Epilepsy

Shravan Sivakumar 1, Mehdi Ghasemi 1, * and Steven C. Schachter 2, 3, 4, *

1 Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA
2 Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
3 Harvard Medical School, Boston, MA 02114, USA
4 Consortia for Improving Medicine with Innovation & Technology (CIMIT), Boston, MA 02114, USA
* Correspondence: mehdi.ghasemi@umassmemorial.org (M.G.); sschacht@bidmc.harvard.edu (S.C.S.)

Abstract: N-methyl-D-aspartate receptors (NMDARs) are widely distributed in the central nervous system (CNS) and play critical roles in neuronal excitability in the CNS. Both clinical and preclinical studies have revealed that the abnormal expression or function of these receptors can underlie the pathophysiology of seizure disorders and epilepsy. Accordingly, NMDAR modulators have been shown to exert anticonvulsive effects in various preclinical models of seizures, as well as in patients with epilepsy. In this review, we provide an update on the pathologic role of NMDARs in epilepsy and an overview of the NMDA antagonists that have been evaluated as anticonvulsive agents in clinical studies, as well as in preclinical seizure models.

Keywords: N-methyl-D-aspartate (NMDA) receptor; seizure; epilepsy; NMDA receptor antagonist; clinical trial

1. Introduction

Epilepsy is a common neurological disorder, affecting about 1% of the general population, approximately 50 million people worldwide [1]. Despite the widespread use of anti-seizure medications (ASMs) over the past few decades in the management of epilepsy, about one-third of patients with epilepsy show no response to anti-seizure medication [2, 3]. The International League Against Epilepsy (ILAE) defines drug-resistant epilepsy (DRE) as the “failure of adequate trials of 2 tolerated, appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom” [4]. The incidence of DRE was recently found to be about 19.6% of total epilepsy cases [5]. This calls for the need for further understanding of the mechanisms implicated in epileptogenesis, which could bolster treatment options.

Several pathways have been implicated to play a role in epileptogenesis [6], among which the desynchrony between neuronal excitation and inhibition is widely speculated to majorly contribute. Previous research on seizures from temporal lobe epilepsy (TLE) has demonstrated that glutamate levels rise in the extracellular fluid and that glutamate can directly activate N-methyl-D-aspartate receptors (NMDARs) and cause neuroexcitatory toxicity [7]. An overwhelming body of evidence exists centered around the role of NMDARs in several neurological disorders, including epilepsy. More recently, a sub-type of autoimmune encephalitis has been found to be associated with ~20% of epilepsy cases. This has further highlighted the role of the NMDAR complex in epileptogenesis [8]. These factors have formed the basis of research directed at both the preventive and therapeutic roles of NMDAR-modulating therapy in the management of neurological disorders.

The NMDAR complex is characterized by excitatory neurotransmitters (glutamate receptors) located on the synapses of interneurons regulating the balance between neuronal excitation and inhibition, and it has been implicated to play a role in epilepsy [9, 10]. Several
animal models have consistently shown that blocking NMDARs is effective in both the prevention and reversal of neurological disorders, including epilepsy [11]. A high sensitivity to modulation, as well as a proclivity for negative side effects, including neurotoxicity, has made it challenging for the development of newer agents. In this review, we highlight the role of NMDAR-guided therapy by providing an overview of the key pathophysiology, linking the role of the NMDAR complex in epilepsy with an emphasis on drugs currently in use, as well as on-going preclinical studies utilizing NMDAR-modulating therapy.

2. NMDAR Complex

The NMDAR is one of the ionotropic glutamate receptors (iGluR) serving as a target for action of the major excitatory neurotransmitter glutamate at the presynaptic terminal and post-synaptic membrane in the central nervous system (CNS) [12].

The NMDAR complex contributes to normal brain functioning, which begins in utero. By providing neuronal excitation that promotes survival and efficient connectivity, NMDARs are involved in neurodevelopment [13]. This developmental period extends from the third trimester of pregnancy to the first several years of postnatal life in humans. NMDAR transmission is involved in the connectivity between hippocampal and prefrontal circuits [14]. NMDAR activation in hippocampal pathways controls an activity-dependent synaptic modification called long-term potentiation (LTP), contributing to learning and new memory formation [15,16].

In addition, the NMDAR complex is involved in spatial learning [17]. Furthermore, NMDAR transmission is involved in persistent neuronal firing, which has been implicated in underlying neurocognitive disorders and particularly in aversive mental states [18].

The receptor complex consists of a heterotetrameric structure in which an NR1 subunit is ubiquitous, and there are varying combinations of NR2 (GluN2) or NR3 (GluN3) subunits, with multiple binding sites for glutamate, polyamine, Mg$^{2+}$, and glycine (Figure 1). The varying combinations of subunit binding sites determine the pharmacological regulation of the NMDAR. The glutamate binding site is situated on the NR2 subunit, and, similarly, the glycine binding site is situated on the NR1 subunit. These binding sites exhibit varying neuroanatomic expressions.

![Figure 1. Schematic representation of N-methyl-D-aspartate receptor (NMDAR) complex and binding sites for GluN1 and GluN2 for some NMDAR antagonists. Ifenprodil and eliprodil mainly bind to GluN2B subunit. Mg$^{2+}$, dizocilpine (MK-801), ketamine, and memantine act as noncompetitive antagonists with binding sites inside the ion channel pore region.](image-url)
In the resting state, the channel is blocked by Mg$^{2+}$ and remains equally permeable to Na$^+$ and Ca$^{2+}$ ions [19,20]. Membrane depolarization relieves the Mg$^{2+}$ blockage, and the resulting neuronal excitation in-term mediates the NMDAR responses contributing to the neurotoxicity from excess Ca$^{2+}$ ions. Neurotoxicity resulting from overexcitation has been widely speculated to play a major role in epilepsy [21].

2.1. NMDA Trafficking

NMDAR delivery to synapses and intracellular trafficking both depend on PDZ proteins [22]. NMDARs are not evenly distributed once they reach the neural surface, showing a higher concentration in postsynaptic densities and a lower one in extra-synaptic compartments [23]. Surface NMDARs are dynamically anchored in the postsynaptic density (PSD) region via an interaction between GluN2 subunits and proteins with PDZ-binding domains [24]. However, there are still questions about where receptor membrane trafficking occurs. The dysregulation of NMDAR trafficking has been implicated in several neuropsychiatric disorders in the past, and increasing evidence points to their involvement in epilepsy [25].

The trafficking of NMDARs to membranes was noted through an increase in synaptic and/or presynaptic NR1 subunits in a rat model of status epilepticus (SE) [26]. This increase in NMDA expression coincides with the loss of synaptic inhibitions through the internalization of (GABA)$_A$ receptors implicated in the propagation of seizures to SE [27]. Furthermore, GRIN2A mutations can impact NMDAR trafficking overall by altering the levels of GluN2A proteins and by altering GluN2A membrane trafficking [26]. The defective interaction of protein binding sites involved in vesicular trafficking (SNX27) due to the phosphorylation of GluN2A has also been implicated in NMDAR trafficking defects [29]. In animal models and human epileptic brain tissue, G-protein-coupled receptor 40 (GPR40) affected N-methyl-D-aspartate (NMDA) receptor-mediated synaptic transmission through the regulation of NR2A and NR2B expressions on the surface of neurons [30]. Furthermore, the endocytosis of NMDARs and the binding of GPR40 with NR2A and NR2B were regulated through GPR40 [30]. Alterations in the interactions involved in NMDAR trafficking could open new avenues of therapeutic targets to alleviate neuronal overexcitation in epilepsy.

2.2. NMDA Modulation (Glycine and Other Sites)

The binding of a co-agonist at the glycine-mediated site (GMS) is necessary for NMDAR action, in addition to glutamate. The modulation of the GMS of the NMDAR is low, given the low saturation in vivo despite the high CSF concentrations of glycine [31]. D-serine serves as a major endogenous co-agonist of the NMDAR, and D-serine levels were recently found to be upregulated in intractable epilepsy [32–34]. It is possible that endogenous glycine does not fully stimulate NMDARs as suggested by the selective potentiation of the convulsant activity of NMDA by D-serine [35]. However, the therapeutic effect of glycine modulation is severely limited given the requirements of a high dose and a narrow therapeutic window and its severe adverse effects, such as oxidative damage, neurotoxicity, and nephrotoxicity [36].

When compared to other NMDAR subtypes, NR2B-containing receptors appear to contribute more favorably to pathogenic processes, such as epilepsy caused by excessive glutamatergic pathway activation. This makes them more of a preferential target for modulation [37]. A common mechanism involved in the allosteric modulation of NMDARs is through proton selectivity by shifting the pKa of the proton sensor [38,39]. This mechanism is involved in selective allosteric inhibition via ifenprodil, polyamines, and extracellular zinc at NR2A-containing receptors [40,41]. The allosteric modulation of NMDARs through a novel synthetic analogue of 24(S)-hydroxycholesterol-SGE-301 prevented the NMDAR dysfunction in patients with autoimmune encephalitis from NMDAR antibodies in cultured neurons [42]. A potential mechanism implicated was the prolonged decay time of NMDAR-dependent spontaneous excitatory postsynaptic currents suggesting a prolonged
open time of the channel. More recently, miR-219, a microRNA, was implicated to play a regulatory role in the modulation of excitatory neurotransmission in epilepsy [43]. The upregulation of NR1 subunits was noted through an inverse relationship between miR-219 and NMDA-NR1 expression in the amygdala and hippocampus of patients with intractable mesial temporal lobe epilepsy [43].

2.3. NMDA mGluR and AMPA Interactions

Metabotropic glutamate receptors (mGluRs), which are a subtype of glutamate receptors, are members of G-protein-coupled receptors (GPCRs) involved in intracellular secondary messenger systems modulating neuronal excitability, which is of relevance in epilepsy [44]. mGluR5 responses have been found to be regulated by the activation of NMDARs via a protein kinase C (PKC) pathway [45,46]. Prior work has shown that mGluR5-positive modulators can attenuate the behavioral effects of NMDAR antagonists, PCP and MK-801 [47,48]. Despite the fact that there have not yet been any large clinical trials focusing on mGluR5 in epilepsy, selective group I mGluR antagonists were explored for their anticonvulsant effects in rodent models of epilepsy by Chapman et al., 2000, and Yan et al., 2005 [49,50]. However, the limitations behind their potential usefulness as anticonvulsant drugs would be due to the dominant effects of mGluR1 in cerebellar function and motor control [51]. Accordingly, patients who express autoantibodies against mGluR1 [52] or Homer-3 (a scaffolding protein for mGluRs) [53] exhibit signs of cerebellar dysfunction, such as ataxia.

The increased phosphorylation of NMDA and AMPA receptor subunits in rat models has been implicated in the regulation of synaptic plasticity and memory consolidation via the activation of ERK1/2 signaling [54]. In humans, Anti-GluA1 and Anti-GluA2 antibodies that target AMPAR subunits have been found in patients with epilepsy caused by autoimmune limbic encephalitis [55,56]. However, AMPAR autoantibodies were found to not have any interaction with NMDARs [57]. More recently, a combination of NMDAR and AMPAR antagonists in a mice model demonstrated that these receptor interactions could potentially contribute to delayed epileptogenesis through granule cell dispersion [58]. Though the response was a delay rather than the prevention of epileptogenesis, further clinical trials are warranted to study this interaction.

3. NMDAR Alterations and Their Role in Human Epilepsy

The alterations in NMDARs in epilepsy have been extensively investigated in the past through the use of a variety of techniques, such as gene expression, immunoblotting, and binding affinity techniques.

Through an in situ hybridization technique, Bayer et al., in 1995, showed that a loss of NR1-positive cells was associated with overall neuronal loss involving pyramidal cells [59]. Furthermore, NR2 subunit mRNA levels were increased in patients with hippocampal sclerosis (HS) [60]. In the dentate gyrus, there appears to be an increase in NR2 immunoreactivity that is associated with abnormal mossy fiber sprouting in this region [61]. It has been consistently demonstrated that the inhibition of the glutamate binding site (NR2 subunit) decreases granule cell hyperexcitability in cases showing mossy fiber sprouting in hippocampi [62–64]. More direct evidence from pyramidal neurons in human cortical slice preparations from patients with mesial temporal lobe epilepsy showed that an increased endogenous activity of NMDARs was associated with neuronal hyperexcitability [65]. More recently, in focal epilepsies, through the use of [(18)F]GE-179, a ligand that selectively binds to open NMDAR ion channels, McGinnity CJ et al. demonstrated NMDA channel overactivity through the use of positron emission tomography (PET) [66]. An alteration in NMDAR subunit (NR2B) composition in cortical dysplasia tissue has been shown to contribute to functional abnormalities due to decreased Mg$^{2+}$ sensitivity of the receptor, which results in neuronal hyperexcitability [67]. In addition, increases in the levels of NR2B and 2D subunit mRNAs and functional NR2B-containing receptors (using a ligand-binding method) were noted in tuberous sclerosis [68]. Dysplastic neurons showed increased ex-
pressions of NR2B and 2C subunit mRNAs, whereas only NR2D mRNA was upregulated in giant cells, suggesting that dysplastic neurons and giant cells contribute differently to epileptogenesis in the tuberous sclerosis complex [68]. These studies emphasize that various alterations in the different subunits of NMDARs (especially NR1 and NR2 subunits) in different brain regions could be responsible for seizure development accordingly among the several types of epilepsies.

In human patients with symptomatic epilepsies, the regulation of the GluN2B subunit of the NMDAR complex via NRG1-ErbB4-Src signaling pathways was identified as a potential modulating target through the use of the immunoblotting technique [69]. In patients with intractable temporal lobe epilepsies, D-serine and NMDAR1 expressions were significantly increased [34]. These observations highlight the importance of neurochemical targeting, which can be further explored in the future to guide anti-NMDAR complex therapies.

Moreover, a variety of animals models of seizures and epilepsy have demonstrated alterations in NMDAR expressions and protein levels, although the results vary depending on the NMDAR subunits, brain regions, and animal species assessed. This has been comprehensively reviewed in the literature [33,69–71].

3.1. Genetic Mutations of the NDMA Receptor

Various genetic expressions of the subunits of the NMDAR (GluN1, GluN2A-2D, and GluN3A-3B) can contribute to the development of distinct clinical phenotypes [72,73]. The genetic mutations in patients with epilepsy are classified broadly as loss-of-function, no-change, and gain-of-function mutations [73].

The GluN1 subunit, encoded by GRIN1, is typically involved in loss-of-function mutations contributing to structural changes resulting in a wide range of epilepsies of variable semiology (spasms, tonic and atonic seizures, hypermotor seizures, focal dyscognitive seizures, febrile seizures, generalized seizures, status epilepticus, myoclonic seizures, etc.) [74]. Reportedly, up to half of GRIN1 mutations are loss-of-function mutations, with the rest being gain-of-function mutations. Hence, the co-existence of both hypo-functioning and hyper-functioning NMDARs within the same disease phenotype invariably contributes to electrophysiological imbalance [10,12]. However, this relation of NMDAR function to the pathogenesis of epilepsy still needs further clarification. GRIN2A mutations, which can alter the GluN2A receptor, occur more so than any other of the NMDAR subunit mutations [75]. About 70% of GRIN2A variants are likely to lead to the development of epilepsy, whereas 30% of individuals with GRIN2B variants have epilepsy [76,77]. GluN2 subunit mutations may control epileptiform abnormalities arising from the hippocampus [78]. GRIN2D mutations are associated with treatment refractory epileptic encephalopathy [79].

Various alterations in subunits in different brain regions are, thus, held accountable for seizure development in different types of epilepsies. Identifying receptor mutations has, hence, been implicated to contribute to a personalized medicine approach in epilepsy treatment. Modeling NMDAR dysfunction with neurons derived from human induced pluripotent stem cells (iPSCs), as well as identifying signaling pathways, has been suggested to further contribute to the development of drugs targeting the NMDAR complex of gene regulatory variants [80].

3.2. Anti-NMDAR Encephalitis

Autoimmune encephalitis from anti-NMDAR antibodies has gained significant attention over the past decade [81,82] to the extent of being regarded as its own entity of epilepsy [83,84]. Anti-NMDA-NR2A/B antibodies are present in ~20% of patients with epilepsy [8]. The autoantibodies against NMDARs can cause a reversible loss of NMDAR function on the surface of neurons [85]. Several mechanisms are involved:

(a) Internalization of NMDAR,
(b) Disruption of interaction of NMDAR with EphB2R,
Decreased long-term potential (LTP), which can lower the threshold for seizures [86–89].

Reductions in excitatory neurotransmission caused by NMDAR antibodies in an in vitro rat model may play a role in NMDA encephalitis [90]. These mechanisms invariably result in a state of excitatory and inhibitory chemical imbalance contributing to seizures in a significant number of patients. These are typically improved by the prompt use of immunomodulatory therapy [91]. A marked decrease in anti-NMDA-NR1 antibody titers was seen following the administration of steroids, intravenous immunoglobulin G (IVIG), or plasmapheresis/plasma exchange, which are part of the first-line management strategies, and following the administration of steroid-sparing agents: rituximab, cyclophosphamide, or both [85,92,93].

4. NMDAR Modulators Currently in Use

4.1. Ketamine

Ketamine acts as a noncompetitive NMDA antagonist and has low affinity for the NMDAR at the phencyclidine site within the ionotropic channel [94]. It was first synthesized in 1962. Conventionally used as an anesthetic agent due to its rapid onset of action and short half-life, ketamine induces a state of “dissociative anesthesia” resulting from an overall CNS depressant effect rather than an inhibitory effect [66,95]. The anticonvulsant effects of ketamine can augment the seizure protective effect of benzodiazepine loading [96,97]. This therapeutic benefit may result from the upregulation of NMDARs during prolonged seizures at the same time when there is an overall decrease in sensitivity to GABA agonists [98–100].

Animal models have consistently shown the synergistic anticonvulsant effects of ketamine therapy in combination with other antiepileptic medications demonstrating both dose- and time-dependent adjuvant effects [101,102]. A multicenter retrospective study provided preliminary data on the safety and efficacy of intravenous ketamine use in the treatment of refractory status epilepticus, which is defined as seizure activity that does not respond to two antiepileptic drugs at appropriate doses [103]. High-dose and the early initiation of ketamine infusions (2.2 mg/kg/h) were associated with a decrease in seizure burden in patients with super-refractory status epilepticus (SRSE) [104]. The favorable effect on the hemodynamic profile, which is due to ketamine’s sympathomimetic properties, unique benefits of conscious sedation, and overall efficacy in treating refractory seizures, makes ketamine an agent to consider using in the management of patients with severe acute traumatic brain injury [105–107]. In critically ill patients where polypharmacy is a concern, ketamine use can limit the need for the further escalation of sedation and thereby help to avoid the need for intubation [108,109]. Further prospective randomized control trials are required to establish a consensus statement on dosing ketamine in refractory epilepsy management in adult and pediatric populations.

The adverse effects of ketamine infusions include neuropsychiatric symptoms, such as hallucinations and delirium, and arrhythmias. There has been a rare report of new-onset seizures in a pediatric patient [100]. Ketamine has been found to induce dose-dependent neuronal injury in animal models through apoptosis, particularly in the frontal cortex and hippocampal regions [110,111]. This, at the same time, is offset by the neuroprotective effect conferred by ketamine through an increase in regional cerebral blood flow volumes, thereby limiting the damage from an incomplete cerebral ischemia [112,113]. More recently, the therapeutic effect of ketamine has been explored in targeted therapy on spreading depolarizations, which represent a unique pathophysiology contributing to secondary injury progression in severe acute brain injury [114–116]. Furthermore, an interplay between seizures and spreading depolarizations has been suggested [116,117]. This further emphasizes the fact that NMDARs are involved in this epiphenomenon of secondary brain injury progression. The prevention of secondary brain injury spread has potential to improve outcomes in critically ill patients with sub-arachnoid hemorrhage, traumatic brain injury, and malignant ischemic strokes.
4.2. Memantine

Memantine is a noncompetitive, open-channel NMDAR antagonist that blocks NMDAR ion channels by binding to or near Mg$^{2+}$ binding sites preferentially when the receptor channel is open, thereby inhibiting the prolonged influx of Ca$^{2+}$ ions with near-normal physiological NMDA activity [118]. The efficacy of memantine as an anticonvulsant for both monotherapy and in combination with other AEDs was explored in preclinical work in the early 1980s [119–121].

In a lithium–pilocarpine mice model, memantine prevented cognitive impairments post-status epilepticus [122]. In a pentylenetetrazole (PTZ) model of seizures, memantine prevented convulsions and the development of morphological changes [123]. Memantine had a significant neuroprotective effect on hippocampal and cortical neurons in culture against glutamate and NMDA excitotoxicity [124]. A mice model showed evidence of a decrease in the frequency of induced seizures with the addition of memantine [125]. However, the addition of memantine to the AED regimen in GRIN2B-mutation-related encephalopathy did not result in any significant decrease in the frequency of seizures in a group of six patients [126].

Given the paucity of clinical data, more clinical trials testing the anticonvulsant effects of memantine as an add-on therapy on seizure types in patients with epilepsy are needed.

4.3. Amantadine

Amantadine was originally used in the management of influenza. It acts by increasing the release and inhibiting the reuptake of dopamine in the brain. In addition to the several other pharmacological actions of amantadine, its role in NMDAR blockage by increasing the rate of channel closure was demonstrated in the early 1990s [127].

The safety and efficacy of amantadine as an add-on therapy in pediatric refractory generalized seizures was first evaluated in a small case series of four patients by Shahar et al. in 1993 [128,129]. In a larger retrospective review of 13 patients, a target amantadine dose of 4 to 7 mg/kg/day was utilized in conjunction with other AEDs. A total of 58% of patients had at least a 50% seizure reduction, with the majority (nearly 86%) of responders sustaining a seizure reduction greater than 90% at 12 months following treatment initiation [130]. Of note, no renal, hepatic, or hematologic toxicity was noted in this study, and other adverse effects included vomiting, behavioral changes, headache, dizziness, and weight loss.

Its favorable pharmacological profile, including the potential improved effects on cognitive recovery [131–133], make amantadine a promising agent of choice to explore in critically ill patients with refractory epilepsy. Further larger, multicenter trials are needed to study the efficacy of amantadine add-on therapy in refractory epilepsy.

4.4. Magnesium Sulphate

The potential for convulsions to occur in states of Mg$^{2+}$ depletion prompted some researchers to investigate the metabolism of this metal in epilepsies [134]. Experiments have shown that Mg$^{2+}$ blocks Ca$^{2+}$ within the NMDAR channel, which, in turn, is relieved by cellular depolarization [135]. The anticonvulsant effects of the systemic administration of Mg$^{2+}$ have been studied in animal models [136]. An increase in brain Mg$^{2+}$ concentrations in rat brains has been found to be associated with an increased seizure threshold and resistance to NMDA-stimulated hippocampal seizures [137]. The inhibition of NMDARs is central to Mg$^{2+}$ anticonvulsant effects [138].

In two patients with juvenile-onset Alpers’ syndrome, intravenous Mg$^{2+}$ treatment reduced refractory epilepsy with recurring status epilepticus and bouts of epilepsy partialis continua [139]. Furthermore, in infants with infantile spasms, the addition of magnesium sulphate to adrenocorticotropic hormone (ACTH) showed significantly improved durations of seizure-free periods in an open-label, randomized, controlled study [140]. In humans, systemic administrations of magnesium sulphate are the standard of care in the management of eclampsia in pregnancy [141]. Concerns remain over the possibilities of hypermagnesemia toxicity in eclampsia treatment [142].
4.5. Felbamate

Felbamate is a propanediol dicarbamate derivative that was first approved as an ASM by the U.S. Food and Drug Administration (FDA) in 1993 [143]. Several mechanisms, including the blockage of voltage-gated sodium channels and dual actions on both excitatory (NMDA) and inhibitory (GABA) mechanisms, have been postulated to contribute to the anticonvulsant effect of felbamate [144].

In addition, the specific selectivity of felbamate to the NR2B subunit of NMDA has been noted. NR2B mutations have been implicated to play a role in epileptogenesis in mouse models [145]. Felbamate’s efficacy as add-on therapy is well-established for intractable partial seizures, infantile spasms, and Lennox-Gastaut syndrome [146,147]. Serious adverse effects of aplastic anemia and liver failure have been reported, which has limited the use of felbamate as add-on therapy in partial epilepsy [148].

4.6. Remacemide

Remacemide is a noncompetitive, low-affinity, NMDAR antagonist. A rapid and reversible inhibition of the NMDA current was first observed in rat forebrain membranes [149]. Its anticonvulsant effects in animal models of epilepsy were observed in a dose range of 6–60 mg/kg [150]. Remacemide hydrochloride was shown to have therapeutic activity in patients with medically refractive epilepsy at a dose of 600 mg/day [151]. Chadwick et al. [152] and Jones et al. [153] evaluated the role of the remacemide QID regimen as an add-on in medically refractory epilepsy.

It is worth noting that in patients with newly diagnosed epilepsy, when compared to other AEDs, such as carbamazepine, remacemide had no benefit as monotherapy [154]. A double-blind, parallel-group trial comparing remacemide with carbamazepine in partial or generalized tonic–clonic seizures showed a better cognitive and psychomotor profile at the cost of inferior seizure recurrence with the use of remacemide [155]. Some common adverse effects observed are dizziness, somnolence, and gastrointestinal symptoms. Diplopia and fatigue have been observed when used as adjunctive therapy with conventional AEDs [156].

4.7. Riluzole

2-Amino-6trifluoromethoxy benzothiazole (riluzole) was first noted to have anticonvulsant effects in the 1980s [157]. Several mechanisms involving glutamate modulation were noted. The presynaptic release of glutamate was reduced by the inhibition of voltage-gated Na\(^+\) currents in hippocampal neurons [158]. Riluzole can prevent Ca\(^2+\) entry via the NMDA channel, thereby blocking NMDAR activation [159]. A modulatory effect of riluzole on glutamate clearance has also been noted on the glutamate transporters expressed on neurons and glia [160].

Preclinical data have shown anticonvulsant effects in a variety of seizure models; in the rat dentate gyrus of both pilocarpine- and GBL-induced seizure models, riluzole was found to be more effective in reducing seizure activity than VPA [161]. Riluzole reduced seizure duration in a rat electroconvulsive shock model of epilepsy [162]. Furthermore, the inhibition of spontaneous glutamine transport by riluzole was demonstrated in hippocampal neurons [163]. In a CA3 in vitro rat slice model, the sodium channel blockage of riluzole resulted in decreased hippocampal epileptiform activity [164]. Despite the evidence from animal models, the effects of riluzole in human patients with epilepsy are yet to be evaluated in any clinical study.

4.8. Dizocilpine or MK-801

MK-801 is a noncompetitive NMDA antagonist that was first demonstrated to have antiepileptic effects in a model of induced seizures through the low-frequency kindling technique by Minabe et al. in 1992 [165]. MK-801 is a special NMDAR antagonist due to its well-demonstrated effects in both use-dependent and voltage-dependent manners via the blockade of ion permeation [166–169]. A large number of preclinical investigations have demonstrated its anticonvulsant properties in several models, including seizures
induced by NMDA, quinolinic acid, lindane, 4-aminopyridine, caffeine, picrotoxin, bicuculline, cocaine, kainic acid, strychnine, pentylentetrazole (PTZ), or hyperbaric oxygen in rodents [170–181]. However, more recent evidence based on the stargazer mice trial suggests that MK-801 has a paradoxical pro-seizure effect [182].

In tetramethylenedisulfotetramine (TMDT)-induced tonic–clonic seizures, the combination of diazepam and MK-801 had a synergistic anticonvulsant effect [183]. Status epilepticus was aborted, and mortality was eliminated with the combination of diazepam and dizocilpine in a rat model of SE induced by very high doses of lithium and pilocarpine [178], as well as in a model of soman-induced SE [184,185]. These observations suggest the possibility of clinical benefits of combinations of MK-801 and other anti-seizure medications. Due to concerns regarding the schizophrenia-like behaviors frequently noted in animal models, MK-801 has not been explored in human subjects [186].

4.9. Dextromethorphan

Initially introduced as an anti-tussive agent, owing to its several mechanisms of actions, dextromethorphan has found potential use as both an analgesic and anticonvulsive agent [187–189]. Dextromethorphan was noted to have noncompetitive NMDAR blocking effects with an efficacy similar to that of controlled substances, such as phencyclidine and ketamine, at high doses.

Dextromethorphan, added to existing AEDs at doses of 40 mg and 50 mg every 6 h (160 and 200 mg/day, respectively) for 8 weeks, resulted in significant improvements in seizure control in patients with drug-resistant, localization-related epilepsies [189]. Furthermore, a randomized, open-label trial of dextromethorphan in Rett’s syndrome showed evidence of significant dose-dependent improvements in clinical seizures [190]. This preliminary evidence needs further validation in larger cohorts.

The adverse effects of dextromethorphan include nystagmus, slurred speech, lightheadedness, and fatigue at high doses [191]. In addition, sudden tonic–clonic movements and confusion have been reported to be caused by the toxicity associated with dextromethorphan in a case report [192].

4.10. Ifenprodil

Ifenprodil (4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol) is a selective antagonist of the GluN2B subtype of NMDARs [193]. The anticonvulsant effect of ifenprodil has been investigated in several animal models of epilepsy, including induced seizures by NMDA, spermine, lindane, and PTZ in rodents [194–198]. Furthermore, both age-dependent and activation-dependent anticonvulsant actions of ifenprodil were noted [199]. In five human patients with refractory epilepsy caused by malformations of cortical development (MCD), ifenprodil had specific antiepileptic effects by reducing pyramidal cell neural excitability [200]. More recently, in temporal lobe epilepsy medicated by the GluN2B subtype of NMDARs, intraperitoneal ifenprodil administration (20 mg/kg) resulted in the suppression of a number of chronic seizures and an anti-ictogenic effect [201].

When used in combination with other AEDs, the threshold for seizures was increased without influencing the anticonvulsant actions of other drugs (carbamazepine, diphenylhydantoin, phenobarbital, and valproate) [202].

5. Preclinical Studies with Newer NMDAR Modulators

A variety of NMDAR modulators have been investigated in preclinical studies using various seizure models [11]. More recent studies have also tested newer agents that modulate NMDARs (Table 1). In a mouse model on clonic seizures induced by PTC, the involvement of the NMDAR pathway in the anticonvulsant effect of licofelone (dual 5-lipoxygenase/cyclooxygenase inhibitor) was demonstrated by combining the noncompetitive NMDAR antagonist MK-801 with licofelone (5 mg/kg) [203]. In addition, a lower dose of licofelone did not have an anticonvulsant effect [203]. Recently, the use of GNE-0723 (a positive allosteric modulator of GluN2A-subunit-containing NMDARs) reduced low-
frequency oscillatory and epileptiform activities in J20 mice [204]. The GluN2B-selective antagonist Ro 25-6981 suppressed the tonic phase of generalized tonic-clonic seizures in a PTZ model of infantile rats [205].

Table 1. Anticonvulsive effects of newer NMDAR antagonists in pre-clinical studies.

| Substance | Effect on NMDARs | Seizure Model | Effect | Ref. |
|-----------|------------------|---------------|--------|------|
| GNE-0723  | Positive allosteric modulator of GluN2A | Mouse model of Dravet syndrome | ↓ Low-frequency oscillatory and epileptiform activities | [204] |
| Ro 25-6981| Selective GluN2B antagonist | PTZ model in infantile (12-day-old, P12) and juvenile (25-day-old, P25) rats | ↓ PTZ-induced seizures in infantile, but not juvenile, rats | [205] |
| PEAQX     | Selective GluN2A antagonist | PTZ-induced generalized seizures | Age-dependent differences in anticonvulsant effects in PTZ-induced seizures and epilepsy after discharge | [206] |
| DDBM      | Both GluN1 and GluN2 antagonist | Rat ECS model of epilepsy | ↓ Seizure behaviors in rats | [162] |

DDBM, 1 indolyl, [2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde]; ECS, electroconvulsive shock; PTZ, pentylenetetrazole.

6. Adverse Effects of NMDAR Antagonist in Clinical Settings

The inhibition of the major excitatory neurotransmitter glutamate is bound to have adverse effects that can potentially limit its potential for clinical application. In a clinical investigation, the competitive NMDAR antagonist D-CPP-ene increased seizures in three out of eight patients with epilepsy, raising the possibility that a sudden decline in NMDAR function could lead to an imbalance between the excitatory and inhibitory systems [207]. A selective blockade of NMDARs without affecting normal function remains a necessity for acceptability in clinical practice. An ideal agent should hence serve the role of an “uncompetitive” antagonist by relying on prior receptor activation by the agonist [208].

Adverse effects, such as hallucinations, lightheadedness, dizziness, fatigue, headaches, out-of-body sensation, and sensory changes, have been reported with NMDA antagonists. Early memory impairments and schizophrenia-like symptoms have been linked to NMDAR hypofunction with the use of antagonists [209]. An early blockade of NMDARs in rat brains has been found to trigger apoptotic neurodegeneration [210]. Brain growth, long-term potentiation, neuronal migration, and synaptic pruning are all significantly influenced by NMDAR activity [211]. Accordingly, the in utero use of NMDA antagonists may disrupt brain development by contributing directly to the disconnection of circuits between the hippocampus and frontal cortex [212].

Impairments in learning ability and memory as the result of NMDAR antagonist therapy, especially in early life, have been extensively studied in rat models [213,214]. These were notably more evident upon direct NMDAR antagonist injection into the amygdala and hippocampus [215]. In human subjects, following ketamine infusions, disruptions in frontal and hippocampal responses contributing to working memory were demonstrated through the use of fMRI imaging [216]. However, it is worth noting that NMDAR blockade impaired learning consolidation without having any effect on the memory retrieval of previously learned tasks [217,218].

Furthermore, in addition to intravenous administration, as extensively previously discussed, other routes of administration can affect the appearance of specific cytotoxic side effects. For example, spinal cord pathology has been noted with intrathecal administration [219]. The intrathecal administration of ketamine in a therapeutically appropriate concentration and dosage had a deleterious effect on rabbits’ central nervous systems [220]. In dogs, the subarachnoid administration of ketamine was found to be associated with histological spinal cord alterations, including gliosis, axonal edema, central chromatolysis, lymphocyte infiltration, and fibrous thickening of the dura mater [221]. Additionally, a terminally ill patient with cancer who had continuous intrathecal ketamine infusions at
a rate of 5 mg/day for a period of 3 weeks was reported by Karpinski et al. to have post-mortem CNS histological abnormalities of subpial spinal cord vacuolation [222].

7. Conclusions and Perspectives

Overwhelming evidence now indicates that the NMDAR complex plays a critical role in seizure disorders. This comes from both preclinical and clinical studies that have found alterations in NMDAR expression and function in seizure models, as well as in patients with epilepsy. Accordingly, various NMDAR modulators have been tested in various animal models of seizures, and in these studies, they have shown efficacy in suppressing different types of seizures. Although few NMDAR antagonists have been evaluated in clinical trials in epileptic patients, the results are promising overall and have opened a new avenue for the treatment of epilepsy. However, long-term therapy with a newer class of NMDAR antagonists warrants further longitudinal studies, especially to assess their safety in this patient population.

Author Contributions: S.S. outlined the performed rigorous literature search, designed the table, and wrote the manuscript. M.G. conceived and designed the review, outlined the performed rigorous literature search, designed the figure, and edited the manuscript. S.C.S. conceived and designed the review and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: M.G. is supported by a clinical research training scholarship in ALS funded by The ALS Association and The American Brain Foundation, in collaboration with the American Academy of Neurology, and an NIH-funded Wellstone fellowship training grant (NIH 5P50HD060848-15) for research on FSHD.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Fiest, K.M.; Sauro, K.M.; Wiebe, S.; Patten, S.B.; Kwon, C.S.; Dykeman, J.; Pringsheim, T.; Lorenzetti, D.L.; Jetté, N. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology* 2017, 88, 296–303. [CrossRef] [PubMed]

2. Moshé, S.L.; Perucca, E.; Ryvlin, P.; Tomson, T. Epilepsy: New advances. *Lancet* 2015, 385, 884–898. [CrossRef]

3. Pérez-Pérez, D.; Frías-Soria, C.L.; Rocha, L. Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources. *Epilepsy Behav.* 2021, 121, 106430. [CrossRef]

4. Kwan, P.; Arzimanoglou, A.; Berg, A.T.; Brodie, M.J.; Allen Hauser, W.; Mathern, G.; Moshé, S.L.; Perucca, E.; Wiebe, S.; French, J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2010, 51, 1069–1077. [CrossRef] [PubMed]

5. Sultan, B.; Panzini, M.A.; Veilleux Carpentier, A.; Comtois, J.; Rioux, B.; Gore, G.; Bauer, P.R.; Kwon, C.S.; Jetté, N.; Josephson, C.B.; et al. Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis. *Neurology* 2021, 96, 805–817. [CrossRef]

6. Gan, J.; Qu, Y.; Li, J.; Zhao, F.; Mu, D. An evaluation of the links between microRNA, autophagy, and epilepsy. *Rev. Neurosci.* 2015, 26, 225–237. [CrossRef]

7. Albrecht, J.; Zielinska, M. Mechanisms of Excessive Extracellular Glutamate Accumulation in Temporal Lobe Epilepsy. *Neurochem. Res.* 2017, 42, 1724–1734. [CrossRef]

8. Levite, M. GLUTAMATE RECEPTOR ANTIBODIES IN NEUROLOGICAL DISEASES: Anti-AMPA-GluR3 antibodies, Anti-NMDA-NR1 antibodies, Anti-NMDA-NR2A/B antibodies, Anti-mGluR1 antibodies or Anti-mGluR5 antibodies are present in subpopulations of patients with either: Epilepsy, Encephalitis, Cerebellar Ataxia, Systemic Lupus Erythematosus (SLE) and Neuropsychiatric SLE, Sjögren’s syndrome, Schizophrenia, Mania or Stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate Blood Brain Barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and Ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. *J. Neural Transm.* 2014, 121, 1029–1075. [CrossRef]
9. Hendry, S.H.; Schwark, H.D.; Jones, E.G.; Yan, J. Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex. *J. Neurosci.* 1987, 7, 1503–1519. [CrossRef]

10. Hanada, T. Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors. *BioMolecules* 2020, 10, 464. [CrossRef]

11. Ghasemi, M.; Schachter, S.C. The NMDA receptor complex as a therapeutic target in epilepsy: A review. *Epilepsy Behav.* 2011, 22, 617–640. [CrossRef] [PubMed]

12. Paoletti, P. Molecular basis of NMDA receptor functional diversity. *Eur. J. Neurosci.* 2011, 33, 1351–1365. [CrossRef] [PubMed]

13. Mennerick, S.; Zorumski, C.F. Neural activity and survival in the developing nervous system. *Mol. Neurobiol.* 2000, 22, 41–54. [CrossRef]

14. Li, M.; Long, C.; Yang, L. Hippocampal-Prefrontal Circuit and Disrupted Functional Connectivity in Psychiatric and Neurodegenerative Disorders. *BioMed Res. Int.* 2015, 2015, 810548. [CrossRef] [PubMed]

15. Collingridge, G.L.; Bliss, T.V. Memories of NMDA receptors and LTP. *Trends Neurosci.* 1995, 18, 54–56. [CrossRef]

16. Rison, R.A.; Stanton, P.K. Long-term potentiation and N-methyl-d-aspartate receptors: Foundations of memory and neurologic disease? *Neurosci. Biobehav. Rev.* 1995, 19, 533–552. [CrossRef]

17. Morris, R.G.; Anderson, E.; Lynch, G.S.; Baudry, M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. *Nature* 1986, 319, 774–776. [CrossRef]

18. Yang, S.; Seo, H.; Wang, M.; Arnsten, A.F.T. NMDAR Neurotransmission Needed for Persistent Neuronal Firing: Potential Roles in Mental Disorders. *Front. Psychiatry* 2021, 12, 654322. [CrossRef]

19. Lau, C.G.; Takeuchi, K.; Rodenas-Ruano, A.; Takayasu, Y.; Murphy, J.; Bennett, M.V.; Zukin, R.S. Regulation of NMDA receptor Ca2+ signalling and synaptic plasticity. *Biochem. Soc. Trans.* 2009, 37, 1369–1374. [CrossRef]

20. Jahr, C.E.; Stevens, C.F. Calcium permeability of the N-methyl-D-aspartate receptor channel in hippocampal neurons in culture. *Proc. Natl. Acad. Sci. USA* 1993, 90, 11573–11577. [CrossRef]

21. Barker-Haliski, M.; White, H.S. Glutamatergic Mechanisms Associated with Seizures and Epilepsy. *Cold Spring Harb. Perspect. Med.* 2015, 5, a022863. [CrossRef] [PubMed]

22. Kim, E.; Sheng, M. PDZ domain proteins of synapses. *Nat. Rev. Neurosci.* 2004, 5, 771–781. [CrossRef]

23. Ladępęche, L.; Dupuis, J.P.; Groc, L. Surface trafficking of NMDA receptors: Gathering from a partner to another. *Semin. Cell Dev. Biol.* 2014, 27, 3–13. [CrossRef] [PubMed]

24. Bard, L.; Sainlos, M.; Bouchet, D.; Cousins, S.; Mikasova, L.; Breillat, C.; Stephenson, F.A.; Imperiali, B.; Choquet, D.; Groc, L. Dynamic and specific interaction between synaptic NR2-NMDA receptor and PDZ proteins. *Proc. Natl. Acad. Sci. USA* 2010, 107, 19561–19566. [CrossRef] [PubMed]

25. Lau, C.G.; Zukin, R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. *Nat. Rev. Neurosci.* 2007, 8, 413–426. [CrossRef] [PubMed]

26. Wasterlain, C.G.; Naylor, D.E.; Liu, H.; Niquet, J.; Baldwin, R. Trafficking of NMDA receptors during status epilepticus: Therapeutic implications. *Epilepsia* 2013, 54 (Suppl. 5), 78–80. [CrossRef] [PubMed]

27. Mele, M.; Costa, R.O.; Duarte, C.B. Alterations in GABA(A)-Receptor Trafficking and Synaptic Dysfunction in Brain Disorders. *Front. Cell. Neurosci.* 2019, 13, 77. [CrossRef]

28. Addis, L.; Virdee, J.K.; Vidler, L.R.; Collier, D.A.; Pal, D.K.; Ursu, D. Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency—Molecular profiling and functional rescue. *Sci. Rep.* 2017, 7, 66. [CrossRef]

29. Mata Vieira, M.; Nguyen, T.A.; Wu, K.; Badger, J.D.; Collins, B.M.; Anggono, V.; Lu, W.; Roche, K.W. An Epilepsy-Associated GRIN2A Rare Variant Disrupts CaMKIIα Phosphorylation of GluN2A and NMDA Receptor Trafficking. *Cell Rep.* 2020, 32, 10810. [CrossRef]

30. Yang, Y.; Tian, X.; Xu, D.; Zheng, F.; Lu, X.; Zhang, Y.; Ma, Y.; Li, Y.; Xu, X.; Zhu, B.; et al. GPR40 modulates epileptic seizure and NMDA receptor function. *Sci. Adv.* 2018, 4, eaau2357. [CrossRef]

31. Bergeron, R.; Meyer, T.M.; Coyle, J.T.; Greene, R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. *Proc. Natl. Acad. Sci. USA* 1995, 92, 15730–15734. [CrossRef] [PubMed]

32. Møthet, J.P.; Le Bail, M.; Billard, J.M. Time and space profiling of NMDA receptor co-agonist functions. *J. Neurochem.* 2015, 135, 210–225. [CrossRef] [PubMed]

33. Zhu, S.; Paoletti, P. Allosteric modulators of NMDA receptors: Multiple sites and mechanisms. *Curr. Opin. Pharmacol.* 2015, 20, 14–23. [CrossRef] [PubMed]

34. Zhang, X.; Hu, B.; Lu, L.; Xu, D.; Sun, L.; Lin, W. D-serine and NMDA Receptor 1 Expression in Patients with Intractable Epilepsy. *Turk. Neurosurg.* 2021, 31, 76–82. [CrossRef]

35. Singh, L.; Oles, R.J.; Trickelbank, M.D. Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor ion channel complex. *Br. J. Pharmacol.* 1990, 99, 285–288. [CrossRef]

36. Meftah, A.; Hasegawa, H.; Kantrowitz, J.T. D-Serine: A Cross Species Review of Safety. *Front. Psychiatry* 2021, 12, 726365. [CrossRef]

37. Mony, L.; Kew, J.N.; Gunthorpe, M.J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. *Br. J. Pharmacol.* 2009, 157, 1301–1317. [CrossRef]

38. Zhang, J-B.; Chang, S.; Xu, P.; Miao, M.; Wu, H.; Zhang, Y.; Zhang, T.; Wang, H.; Zhang, J.; Xie, C.; et al. Structural Basis of the Proton Sensitivity of Human GluN1-GluN2A NMDA Receptors. *Cell Rep.* 2018, 25, 3582–3590.e3584. [CrossRef]
39. Regan, M.C.; Zhu, Z.; Yuan, H.; Myers, S.J.; Menaldino, D.S.; Tahirovic, Y.A.; Liotta, D.C.; Traynelis, S.F.; Furukawa, H. Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors. Nat. Commun. 2019, 10, 321. [CrossRef]

40. Schreiber, J.A.; Schepmann, D.; Frehland, B.; Thum, S.; Datunashvili, M.; Budde, T.; Hollmann, M.; Strutz-Seebom, N.; Wünsch, B.; Seebom, G. A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors. Commun. Biol. 2019, 2, 420. [CrossRef]

41. Low, C.M.; Zheng, F.; Lyuboslavsky, P.; Traynelis, S.F. Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors. Proc. Natl. Acad. Sci. USA 2000, 97, 11062–11067. [CrossRef] [PubMed]

42. Mannara, F.; Radosevic, M.; Planagumà, J.; Soto, D.; Aguilar, E.; Garcia-Serra, A.; Maudes, E.; Pedrozo, M.; Paul, S.; Doherty, J.; et al. Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis. Brain 2020, 143, 2709–2720. [CrossRef] [PubMed]

43. Hamamoto, O.; Tirapelli, D.P.d.C.; Lizarte Neto, F.S.; Freitas-Lima, P.; Saggioro, F.; Geyer, M.A.; Markou, A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43, 506–509. [CrossRef]

44. Chen, H.-H.; Liao, P.-F.; Chan, M.-H. mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptor modulators by PKC dependent pathway. J. Biomed. Sci. 2011, 18, 19. [CrossRef]

45. Pietraszek, M.; Gravius, A.; Schäfer, D.; Weil, T.; Trifanova, D.; Danysz, W. mGluR5, but not mGluR1, antagonist modifies NMDA-induced phosphorylation and regulation of mGluR5. Pharmacol. Biochem. Behav. 2002, 73, 299–306. [CrossRef]

46. Chen, H.-H.; Liao, P.-F.; Chan, M.-H. mGluR5 positive modulators both potentiate activation and restore inhibition in NMDA receptor modulators by PKC dependent pathway. J. Biomed. Sci. 2011, 18, 19. [CrossRef]

47. Potier, E.; Gauthier, A.; Lecourtier, X.; Bensussan, A.; Martin, D.; Guitel, A.; Arlettaz, R.; Babinet, C. mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43, 1199–1209. [CrossRef]

48. Yan, Q.J.; Rammal, M.; Tranfaglia, M.; Bauchwitz, R.P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002, 43, 1199–1209. [CrossRef]

49. Chapman, A.G.; Nanan, K.; Williams, M.; Meldrum, B.S. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine by the mGluR5 antagonist MPEP. Neuropharmacology 2000, 39, 1567–1574. [CrossRef]

50. Sarantis, K.; Antoniou, K.; Matsokis, N.; Angelatou, F. Exposure to novel environment is characterized by an interaction of N-MDAR2 receptor subunits and activation of ERK1/2 signaling, leading to epigenetic changes and gene expression in rat hippocampus. Proc. Natl. Acad. Sci. USA 2005, 94, 1053–1066. [CrossRef]

51. Kano, M.; Watanabe, T. Type-1 metabotropic glutamate receptor signaling in cerebellar Purkinje cells in health and disease. F1000Research 2017, 6, 416. [CrossRef] [PubMed]

52. Sillevis Smit, P.; Kinoshita, A.; De Leeuw, B.; Moll, W.; Coemans, M.; Jaarsma, D.; Henzen-Logmans, S.; Vecht, C.; De Zeeuw, C.; Sekiyama, N.; et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N. Engl. J. Med. 2000, 342, 21–27. [CrossRef] [PubMed]

53. Höftberger, R.; Sabater, L.; Ortega, A.; Dalmaj; Graus, F. Patient with homo-3 antibodies and cerebellitis. JAMA Neurol. 2013, 70, 506–509. [CrossRef]

54. Sarantis, K.; Antoniou, K.; Matsokis, N.; Angelatou, F. Exposure to novel environment is characterized by an interaction of D1/NMDA receptors underlined by phosphorylation of the NMDA and AMPA receptor subunits and activation of ERK1/2 signaling, leading to epigenic changes in gene expression in rat hippocampus. Neurochem. Int. 2012, 60, 55–67. [CrossRef]

55. Laurido-Soto, O.; Brier, M.R.; Simon, L.E.; McCullough, A.; Bucelli, R.C.; Day, G.S. Patient characteristics and outcome associations with anti-NMDAR encephalitis. J. Neurol. 2019, 266, 450–460. [CrossRef]

56. Höftberger, R.; van Sonderen, A.; Leypoldt, F.; Houghton, D.; Geschwind, M.; Gelfand, J.; Paredes, M.; Sabater, L.; Saiz, A.; Titulaer, M.J.; et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology 2015, 84, 2403–2412. [CrossRef] [PubMed]

57. Peng, X.; Hughes, E.; Moscat, E.H.; Parsons, T.D.; Dalmaj; Balice-Gordon, R.J. Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann. Neurol. 2015, 77, 381–398. [CrossRef] [PubMed]

58. Schidiltzki, A.; Twele, F.; Klee, R.; Waltl, I.; Römermann, K.; Bröer, S.; Meller, S.; Gerhauser, I.; Rankovic, V.; Li, D.; et al. A combination of NMDA and AMPA receptor antagonists retards granule cell dispersion and epileptogenesis in a model of acquired epilepsy. Sci. Rep. 2017, 7, 12191. [CrossRef] [PubMed]

59. Mathern, G.W.; Pretorius, J.K.; Mendoza, D.; Leite, J.P.; Chimelli, L.; Born, D.E.; Fried, I.; Assirati, J.A.; Ojemann, G.A.; Adelson, P.D.; et al. Hippocampal N-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients. Ann. Neurol. 1999, 46, 343–358. [CrossRef] [PubMed]

60. Mathern, G.W.; Pretorius, J.K.; Kornblum, H.I.; Mendoza, D.; Lozada, A.; Leite, J.P.; Chimelli, L.M.; Fried, I.; Sakamoto, A.C.; Assirati, J.A.; et al. Human hippocampal AMPA and NMDA mRNAs levels in temporal lobe epilepsy patients. Brain 1997, 120 Pt 11, 1937–1959. [CrossRef] [PubMed]

61. Mathern, G.W.; Leite, J.P.; Babb, T.L.; Pretorius, J.K.; Kuhlman, P.A.; Mendoza, D.; Fried, I.; Sakamoto, A.C.; Assirati, J.A.; Adelson, P.D. Aberrant hippocampal mossy fiber sprouting correlates with greater NMDAR2 receptor staining. Neuroreport 1996, 7, 1029–1035. [CrossRef] [PubMed]
62. Franck, J.E.; Pokorny, J.; Kunkel, D.D.; Schwartzkroin, P.A. Physiologic and morphologic characteristics of granule cell circuitry in human epileptic hippocampus. *Epilepsia* 1995, 36, 543–558. [CrossRef] [PubMed]
63. Isokawa, M.; Levesque, M.F. Increased NMDA responses and dendritic degeneration in human epileptic hippocampal neurons in slices. *Neurosci. Lett.* 1991, 132, 212–216. [CrossRef]
64. Masukawa, L.M.; Higashima, M.; Hart, G.J.; Spencer, D.D.; O’Connor, M.J. NMDA receptor activation during epileptiform responses in the dentate gyrus of epileptic patients. *Brain Res.* 1991, 562, 176–180. [CrossRef]
65. Banerjee, J.; Banerjee Dixit, A.; Tripathi, M.; Sarkar, C.; Gupta, Y.K.; Chandra, P.S. Enhanced endogenous activation of NMDA receptors in pyramidal neurons of hippocampal tissues from patients with mesial temporal lobe epilepsy: A mechanism of hyperexcitation. *Epilepsy Res.* 2015, 117, 11–16. [CrossRef]
66. McGinnity, C.J.; Koepp, M.J.; Hammers, A.; Riaño Barros, D.A.; Pressler, R.M.; Luthra, S.; Jones, P.A.; Trigg, W.; Micallef, C.; Symms, M.R.; et al. NMDA receptor binding in focal epilepsies. *J. Neurol. Neurosurg. Psychiatry* 2015, 86, 1150–1157. [CrossRef] [PubMed]
67. André, V.M.; Flores-Hernández, J.; Cepeda, C.; Starling, A.J.; Nguyen, S.; Lobo, M.K.; Vinters, H.V.; Levine, M.S.; Mathern, G.W. NMDA receptor alterations from pediatric cortical dysplasia tissue. *Cereb. Cortex* 2004, 14, 634–646. [CrossRef] [PubMed]
68. White, R.; Hua, Y.; Scheithauer, B.; Lynch, D.R.; Henske, E.P.; Crino, P.B. Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers. *Ann. Neurol.* 2001, 49, 67–78. [CrossRef]
69. Zhu, J.M.; Li, K.X.; Cao, S.X.; Chen, X.J.; Zhang, Y.; Geng, H.Y.; Chen, B.Q.; Lian, H.; Zhang, J.M.; et al. Increased NRGl-ErbB4 signaling in human symptomatic epilepsy. *Sci. Rep.* 2017, 7, 141. [CrossRef] [PubMed]
70. André, V.M.; Flores-Hernández, J.; Cepeda, C.; Starling, A.J.; Nguyen, S.; Lobo, M.K.; Vinters, H.V.; Levine, M.S.; Mathern, G.W. NMDA receptor alterations from pediatric cortical dysplasia tissue. *Cereb. Cortex* 2004, 14, 634–646. [CrossRef] [PubMed]
71. Jeon, A.R.; Kim, J.E. PDI Knockdown Inhibits Seizure Activity in Acute Seizure and Chronic Epilepsy Rat Models via S-66. McGinnity, C.J.; Koepp, M.J.; Hammers, A.; Riaño Barros, D.A.; Pressler, R.M.; Luthra, S.; Jones, P.A.; Trigg, W.; Micallef, C.; Symms, M.R.; et al. NMDA receptor binding in focal epilepsies. *J. Neurol. Neurosurg. Psychiatry* 2015, 86, 1150–1157. [CrossRef] [PubMed]
72. Franck, J.E.; Pokorny, J.; Kunkel, D.D.; Schwartzkroin, P.A. Physiologic and morphologic characteristics of granule cell circuitry in human epileptic hippocampus. *Epilepsia* 1995, 36, 543–558. [CrossRef] [PubMed]
73. Xu, X.X.; Luo, J.H. Mutations of N-Methyl-D-Aspartate Receptor Subunits in Epilepsy. *Neurosci. Bull.* 2018, 34, 549–565. [CrossRef] [PubMed]
74. Fry, A.E.; Fawcett, K.A.; Zelnik, N.; Yuan, H.; Thompson, B.A.N.; Shemer-Meiri, L.; Cushion, T.D.; Mugalaasi, H.; Sims, D.; Stoodley, N.; et al. De novo mutations in GRIN1 cause extensive bilateral polymicrogyria. *Brain* 2018, 141, 698–712. [CrossRef] [PubMed]
75. Elmasri, M.; Hunter, D.W.; Winchester, G.; Bates, E.E.; Aziz, W.; Van Der Does, D.M.; Karachaliou, E.; Sakimura, K.; Penn, A.C. Inactivating GluN2B-Containing NMDA Receptor Binding Through the ERK/DAPK1 Pathway. Front. *Neurosci.* 2021, 15, 525615. [CrossRef] [PubMed]
76. Myers, S.J.; Yuan, H.; Kang, J.Q.; Tan, F.C.K.; Traynelis, S.F.; Low, C.M. Distinct roles of GRIN2A and GRIN2B variants in neurological conditions. *F1000Research* 2019, 8, F1000. [CrossRef]
77. Yang, W.; Jiang, Y.; Yuan, D. Novel Mutations and Rare Variants Occurring in NMDA Receptors. *Curr. Opin. Physiol.* 2018, 2, 27–35. [CrossRef]
78. Punnakal, P.; Dominic, D. NMDA Receptor GluN2 Subtypes Control Epileptiform Events in the Hippocampus. *Neuromol. Med.* 2018, 20, 90–96. [CrossRef]
79. Yang, W.; Jiang, Y.; Yuan, D. Novel Mutations and Rare Variants Occurring in NMDA Receptors. *Curr. Opin. Physiol.* 2018, 2, 27–35. [CrossRef]
80. Zhang, W.; Ross, P.J.; Ellis, J.; Salter, M.W. Targeting NMDA receptors in neuropsychiatric disorders by drug screening on human neurons derived from pluripotent stem cells. *Transl. Psychiatry* 2012, 2, 243. [CrossRef] [PubMed]
81. Spatola, M.; Dalmaj, U. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. *Curr. Opin. Neurol.* 2017, 30, 345–353. [CrossRef] [PubMed]
82. Dube, D.; Pittock, S.J.; Kelly, C.R.; McKeon, A.; Lopez-Chiriboga, A.S.; Lennon, V.A.; Gadoth, A.; Smith, C.Y.; Bryant, S.C.; Klein, C.J.; et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. *Ann. Neurol.* 2018, 83, 166–177. [CrossRef] [PubMed]
83. Leypoldt, F.; Armanoue, T.; Dalmaj, U. Autoimmune encephalopathies. *Ann. N. Y. Acad. Sci.* 2015, 1338, 94–114. [CrossRef] [PubMed]
84. Dalmaj, U.; Gleineham, A.J.; Hughes, E.G.; Rossi, J.E.; Peng, X.; Lai, M.; Dessain, S.K.; Rosenfeld, M.R.; Balice-Gordon, R.; Lynch, D.R. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. *Lancet Neurol.* 2008, 7, 1091–1098. [CrossRef] [PubMed]
85. Dalmaj, U.; Lancaster, E.; Martinez-Hernandez, E.; Rosenfeld, M.R.; Balice-Gordon, R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol.* 2011, 10, 63–74. [CrossRef] [PubMed]
86. Ladépêche, L.; Planaguamà, J.; Thakur, S.; Suárez, I.; Hara, M.; Borbely, J.S.; Sandoval, A.; Laparra-Cuervo, L.; Dalmaj, U.; Lakadamyali, M. NMDA Receptor Autoantibodies in Autoimmune Encephalitis Cause a Subunit-Specific Nanoscale Redistribution of NMDA Receptors. *Cell Rep.* 2018, 23, 3759–3768. [CrossRef] [PubMed]
87. Planagumà, J.; Haselmann, H.; Mannara, F.; Petit-Pedrol, M.; Grünewald, B.; Aguilar, E.; Röpke, L.; Martín-Garcia, E.; Titulaer, M.J.; Jercog, P.; et al. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. *Ann. Neurol.* 2016, 80, 388–400. [CrossRef] [PubMed]

88. Planagumà, J.; Leypoldt, E.; Mannara, F.; Gutiérrez-Cuesta, J.; Martín-Garcia, E.; Aguilar, E.; Titulaer, M.J.; Petit-Pedrol, M.; Jain, A.; Balice-Gordon, R.; et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. *Brain* 2014, 138, 94–109. [CrossRef] [PubMed]

89. Wright, S.; Hashemi, K.; Stasiak, L.; Bartram, J.; Lang, B.; Vincent, A.; Upton, A.L. Epileptogenic effects of NMDA receptor antibodies in a passive transfer mouse model. *Brain* 2015, 138, 3159–3167. [CrossRef] [PubMed]

90. Wright, S.K.; Rosch, R.E.; Wilson, M.A.; Upadhya, M.; Dhangar, D.R.; Clarke-Bland, C.; Wahid, T.T.; Barman, S.; Goebels, N.; Kreye, J.; et al. Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDA antibody-mediated encephalitis. *Commun. Biol.* 2021, 4, 1106. [CrossRef]

91. Wandinger, K.P.; Saschenbrecker, S.; Stoecker, W.; Dalmaj, J. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. *J. Neuromunol.* 2011, 231, 86–91. [CrossRef] [PubMed]

92. Irani, S.K.; Vincent, A. NMDA receptor antibody encephalitis. *Curr. Neurol. Neurosci. Rep.* 2011, 11, 298–304. [CrossRef] [PubMed]

93. Finke, C.; Kopp, U.A.; Prüss, H.; Dalmaj, J.; Wandinger, K.P.; Ploner, C.J. Cognitive deficits following anti-NMDA receptor encephalitis. *J. Neurol. Neurosurg. Psychiatry* 2012, 83, 195–198. [CrossRef] [PubMed]

94. Mealing, G.A.; Lanham, T.H.; Murray, C.L.; Small, D.L.; Morley, P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. *J. Pharmacol. Exp. Ther.* 1999, 288, 204–210. [PubMed]

95. Marland, S.; Elliott, J.; Andolfatto, G.; Strapazon, G.; Thomassen, O.; Brandner, B.; Weatherall, A.; Paal, P. Ketamine: Use in anesthesia. *CNS Neurosci. Ther.* 2013, 19, 381–389. [CrossRef]

96. Ghasemi, M.; Shafaroodi, H.; Nazarbeiki, S.; Meskar, H.; Heydarpour, P.; Ghasemi, A.; Talab, S.S.; Ziai, P.; Bahremand, A.; Dehpour, A.R. Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentyleenetetrazole-induced clonic seizures in mice. *Epilepsy Behav.* 2010, 18, 171–178. [CrossRef] [PubMed]

97. Marrero-Rosado, B.M.; de Araujo Furtado, M.; Kundrick, E.R.; Walker, K.A.; Stone, M.F.; Schultz, C.R.; Nguyen, D.A.; Lumley, L.A. Ketamine as adjunct to midazolam treatment following soman-induced status epilepticus reduces seizure severity, epileptogenesis, and brain pathology in plasma carboxylesterase knockout mice. *Epilepsy Behav.* 2020, 111, 10729. [CrossRef]

98. Santoro, J.D.; Filippakis, A.; Chitnis, T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. *Epilepsy Behav. Rep.* 2019, 12, 100326. [CrossRef] [PubMed]

99. Borsato, G.S.; Siegel, J.L.; Rose, M.Q.; Ojar, M.; Feyissa, A.M.; Quinones-Hinojosa, A.; Jackson, D.A.; Rogers, E.R.; Friedman, W.D. Ketamine in seizure management and future pharmacogenomic considerations. *Pharmacogenom.* J. 2020, 20, 351–354. [CrossRef] [PubMed]

100. Meaden, C.W.; Barnes, S. Ketamine Implicated in New Onset Seizure. *Clin. Pract. Cases Emerg. Med.* 2019, 3, 401–404. [CrossRef]

101. Borowicz, K.K.; Luszczki, J.; Czuczwar, S.J. Interactions between non-barbiturate injectable anesthetics and conventional antiepileptic drugs in the maximal electroshock test in mice–an isobolographic analysis. *Eur. Neuropsychopharmacol.* 2004, 14, 163–172. [CrossRef]

102. Martin, B.S.; Kapur, J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. *Epilepsia* 2008, 49, 248–255. [CrossRef]

103. Gaspard, N.; Foreman, B.; Judd, I.S.; Leypoldt, F.; Mannara, F.; Röpke, L.; Martin-Garcia, E.; Titulaer, M.J.; Pollock, A.; et al. Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study. *Epilepsia* 2013, 54, 1498–1503. [CrossRef] [PubMed]

104. Alkhachroum, A.; Der-Nigoghossian, C.A.; Mathews, E.; Massad, N.; Letchinger, R.; Doyle, K.; Chiu, W.-T.; Kromm, J.; Rubinos, C.; Velazquez, A.; et al. Ketamine to treat super-refractory status epilepticus. *Neurology* 2020, 95, e2286. [CrossRef] [PubMed]

105. Godoy, D.A.; Badenes, R.; Belosi, P.; Robba, C. Ketamine in acute phase of severe traumatic brain injury “an old drug for new uses?”. *Crit. Care* 2021, 25, 19. [CrossRef] [PubMed]

106. Hurth, K.P.; Jaworski, A.; Thomas, K.B.; Kirsch, W.B.; Rudoni, M.A.; Wohlfarth, K.M. The Reemergence of Ketamine for Treatment in Critically Ill Adults. *Crit. Care Med.* 2020, 48, 899–911. [CrossRef]

107. Flower, O.; Hellings, S. Sedation in Traumatic Brain Injury. *Emerg. Med. Int.* 2012, 2012, 637171. [CrossRef] [PubMed]

108. Umunna, B.-P.; Tekwani, K.; Barounis, D.; Kettaneh, N.; Kulstad, E. Ketamine for continuous sedation of mechanically ventilated adults? *J. Emerg. Trauma Shock* 2012, 5, 19–23. [CrossRef] [PubMed]

109. Luz, M.; Brandão Barreto, B.; de Castro, R.E.V.; Salluh, J.; Dal-Pizzol, F.; Araujo, C.; De Jong, A.; Chaneques, G.; Myatra, S.N.; Tobar, E.; et al. Practices in sedation, analgesia, mobilization, delirium, and sleep deprivation in adult intensive care units (SAMDS-ICU): An international survey before and during the COVID-19 pandemic. *Ann. Intensive Care* 2022, 12, 9. [CrossRef] [PubMed]

110. Hertle, D.N.; Dreier, J.P.; Woitzik, J.; Hartings, J.A.; Bullock, R.; Okonkwo, D.O.; Shutter, L.A.; Videgon, S.; Strong, A.J.; Kowoll, C.; et al. Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. *Brain* 2012, 135, 2390–2398. [CrossRef]

111. Zou, X.; Patterson, T.A.; Sadovova, N.; Twaddle, N.C.; Doerge, D.R.; Zhang, X.; Fu, X.; Hanig, J.P.; Paule, M.G.; Slikker, W.; et al. Potential neurotoxicity of ketamine in the developing rat brain. *Toxicol. Sci.* 2009, 108, 149–158. [CrossRef] [PubMed]

112. Fujikawa, D.G. Neuroprotective effect of ketamine administered after status epilepticus onset. *Epilepsia* 1995, 36, 186–195. [CrossRef]
113. Långsjö, J.W.; Maksimow, A.; Salmi, E.; Kaisti, K.; Aalto, S.; Oikonen, V.; Hinkka, S.; Aanta, R.; Sipilä, H.; Viljanen, T.; et al. S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. *Anesthesiology* 2005, 103, 258–268. [CrossRef] [PubMed]

114. Carlson, A.P.; Abbas, M.; Alunday, R.L.; Qeadan, F.; Shuttleworth, C.W. Spreading depolarization in acute brain injury inhibited by ketamine: A prospective, randomized, multiple crossover trial. *J. Neurosurg.* 2018, 130, 1513–1519. [CrossRef] [PubMed]

115. Dreier, J.P.; Major, S.; Pannek, H.W.; Woitzik, J.; Scheel, M.; Wiesenthal, D.; Martus, P.; Winkler, M.K.; Hartings, J.A.; Fabricius, M.; et al. Spreading convulsions, spreading depolarization and epileptogenesis in human cerebral cortex. *Brain 2012*, 135, 259–275. [CrossRef] [PubMed]

116. Kramer, D.R.; Fujii, T.; Ohiorhenuan, I.; Liu, C.Y. Interplay between Cortical Spreading Depolarization and Seizures. *Stereotact. Funct. Neurosurg. 2017*, 95, 1–5. [CrossRef] [PubMed]

117. Foreman, B.; Lee, H.; Okonkwo, D.O.; Strong, A.J.; Pahl, C.; Shutter, L.A.; Dreier, J.P.; Ngwenya, L.B.; Hartings, J.A. The Relationship Between Seizures and Spreading Depolarizations in Patients with Severe Traumatic Brain Injury. *Neurocrit. Care 2022*, 37, 31–48. [CrossRef] [PubMed]

118. Chen, H.S.; Pellegrini, J.W.; Aggarwal, S.K.; Lei, S.Z.; Warach, S.; Jensen, F.E.; Lipton, S.A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. *J. Neurosci.* 1992, 12, 4427–4436. [CrossRef]

119. Chojnacka-Wójcik, E.; Tatarczyńska, E.; Maj, J. The influence of memantine on the anticonvulsant effects of the antiepileptic drugs. *Pol. J. Pharmacol. Pharm.* 1983, 35, 511–515. [PubMed]

120. McLean, M.J. In vitro electrophysiological evidence predicting anticonvulsant efficacy of memantine and triflurazin. *Pol. J. Pharmacol. Pharm.* 1987, 39, 513–525. [PubMed]

121. Urbaniska, E.; Dziki, M.; Czuczwar, S.J.; Kleinrok, Z.; Turski, W.A. Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. *Neuropsychopharmacology 1992*, 31, 1021–1026. [CrossRef]

122. Kalemenev, S.V.; Zubareva, O.E.; Sizov, V.V.; Lavrent’eva, V.V.; Lukomskaya, N.Y.; Kim, K.K.; Zaitsev, A.V.; Lukomskaya, V.V.; Lavrentyeva, V.V.; Tumanova, N.L.; Zhuravin, I.A.; Magazanik, L.G. Magnesium deprivation. *Funct. Neurosurg.* 2018, 95, 176–189. [CrossRef] [PubMed]

123. Zaitsev, A.V.; Kim, K.; Vasilev, D.S.; Lukomskaya, N.Y.; Lavrentyeva, V.V.; Tumanova, N.L.; Zhuravin, I.A.; Magazanik, L.G. N-methyl-D-aspartate receptor channel blockers prevent pentylethenetrazole-induced convulsions and morphological changes in rat brain neurons. *J. Neurosci. Res. 2015*, 93, 454–465. [CrossRef] [PubMed]

124. Czuczwar, S.J.; Turski, W.A.; Kleinrok, Z. Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs. *J. Pediatr. Neurosci.* 2019, 14, 247–252. [CrossRef] [PubMed]

125. Sun, Y.; Dhamne, S.C.; Carretero-Guillén, A.; Salvador, R.; Goldenberg, M.C.; Godlewski, B.R.; Pascual-Leone, A.; Madsen, J.R.; Stone, S.S.D.; Ruffini, G.; et al. Drug-Responsive Inhomogeneous Cortical Modulation by Direct Current Stimulation. *Ann. Neurol.* 2020, 88, 489–502. [CrossRef]

126. Platzer, K.; Yuan, H.; Schütz, H.; Winschel, A.; Chen, W.; Hu, C.; Kusumoto, H.; Heyne, H.O.; Helbig, K.L.; Tang, S.; et al. GRIN2B unblock of NMDA receptors: Implications for spike-timing dependent synaptic plasticity. *J. Physiol.* 2017, 594, 224–227. [CrossRef] [PubMed]

127. Kornhuber, J.; Bormann, J.; Hübers, M.; Rusche, K.; Riederer, P. Effects of the 1-amino-adamantanines at the NK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. *Eur. J. Pharmacol. Mol. Pharmacol.* 1991, 206, 297–300. [CrossRef]

128. Shahar, E.M.; Brand, N. Effect of add-on amantadine therapy for refractory absence epilepsy. *J. Pediatr.* 1992, 121, 819–821. [CrossRef]

129. Perry, M.S.; Bailey, L.J.; Kotecha, A.C.; Malik, S.I.; Hernandez, A.W. Amantadine for the treatment of refractory absence seizures in children. *Pediatr. Neurosci.* 2018, 43, 131–136. [CrossRef]

130. Sreedharan, M.; Devadathan, K.; Pathan, H.K.; Chalipat, S.; Mohamed, K.P.A. Amantadine for the Treatment of Refractory Absence Seizures in Children. *J. Pediatr. Neurosci.* 2018, 13, 131–136. [CrossRef]

131. Kruse, H.D.; Orent, E.R.; McCollum, E.V. Studies on Magnesium Deficiency in Animals: I. Symptomatology Resulting from Magnesium Deprivation. *J. Biol. Chem.* 1932, 96, 519–539. [CrossRef]
137. Hallak, M. Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain. *Magnes. Res.* 1998, 11, 117–131. [PubMed]

138. Hallak, M.; Berman, R.F.; Itenkauf, S.M.; Janusz, C.A.; Cotton, D.B. Magnesium sulfate treatment decreases N-methyl-D-aspartate receptor binding in the rat brain: An autoradiographic study. *J. Soc. Gynecol. Investig.* 1994, 1, 25–30. [CrossRef]

139. Visser, N.A.; Braun, K.P.J.; Leijten, F.S.S.; van Nieuwenhuizen, O.; Wokke, J.H.J.; van den Bergh, W.M. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. *J. Neurol.* 2011, 258, 218–222. [CrossRef] [PubMed]

140. Zou, L.P.; Wang, X.; Dong, C.H.; Chen, C.H.; Zhao, W.; Zhao, R.Y. Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: A 24-week, randomized, open-label, follow-up study in China. *Clin. Ther.* 2010, 32, 692–700. [CrossRef] [PubMed]

141. Euser, A.G.; Cipolla, M.J. Magnesium sulfate for the treatment of eclampsia: A brief review. *Stroke* 2009, 40, 1169–1175. [CrossRef] [PubMed]

142. McCubbin, J.; Sibai, B.; Abdella, T.; Anderson, G. Cardiopulmonary arrest due to acute maternal hypermagnesaemia. *Lancet* 1981, 317, 1058. [CrossRef]

143. Sachdeo, R.; Kramer, L.D.; Rosenberg, A.; Sachdeo, S. Felbamate monotherapy: Controlled trial in patients with partial onset seizures. *Ann. Neurol.* 1992, 32, 386–392. [CrossRef]

144. Rho, J.M.; Donevan, S.D.; Rogawski, M.A. Mechanism of action of the anticonvulsant felbamate: Opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. *Ann. Neurol.* 1994, 35, 229–234. [CrossRef] [PubMed]

145. Harty, T.P.; Rogawski, M.A. Felbamate block of recombinant N-methyl-D-aspartate receptors: Selectivity for the NR2B subunit. *Epilepsy Res.* 2000, 39, 47–55. [CrossRef]

146. French, J.; Smith, M.; Faught, E.; Brown, L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology* 1999, 52, 1540–1545. [CrossRef]

147. Prakriya, M.; Mennerick, S. Selective Depression of Low–Release Probability Excitatory Synapses by Sodium Channel Blockers. *J. Exp. Ther.* 1996, 276, 161–168. [CrossRef]

148. Davies, J.A. Remacemide hydrochloride: A novel antiepileptic agent. *Gen. Pharmacol.* 1997, 28, 499–502. [CrossRef]

149. Devinsky, O.; Vazquez, B.; Faught, E.; Leppik, I.E.; Pellock, J.M.; Schachter, S.; Alderfer, V.; Holdich, T.A. A double-blind, placebo-controlled study of remacemide in patients with refractory epilepsy following pre-surgical assessment. *Seizure* 2002, 11, 371–376. [CrossRef] [PubMed]

150. Brodie, M.J.; Vezzani, A.; Buzsaki, G.; Chadwick, D.W.; Bode, T.A.; Boggie, P.M.; Lindstrom, P.; Newman, P.K.; Soryal, I.; Wroe, S.; Holdich, T.A. Remacemide hydrochloride as an add-on therapy in epilepsy: A randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. *Seizure* 2002, 11, 114–123. [CrossRef] [PubMed]

151. Jones, M.W.; Blume, W.T.; Guberman, A.; Lee, M.A.; Pillay, N.; Weaver, D.F.; Veloso, F.; Holdich, T.A. Remacemide hydrochloride as an add-on therapy in epilepsy: A randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen. *Seizure* 2002, 11, 104–113. [CrossRef]

152. Brodie, M.J.; Wroe, S.J.; Dean, A.D.; Holdich, T.A.; Whitehead, J.; Stevens, J.W. Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. *Epilepsy Behav.* 2002, 3, 140–146. [CrossRef]

153. Wenzes, K.A.; Edgar, C.; Dean, A.D.P.; Wroe, S.J. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. *Seizure Behav.* 2009, 14, 522–528. [CrossRef]

154. Bialer, M.; Jehanne, S.I.; Kupferberg, H.J.; Levy, R.H.; Loiseau, P.; Perucca, E. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference (EILAT IV). *Epilepsy Res.* 1999, 34, 1–41. [CrossRef]

155. Miziolek, J.; Meldrum, B.; Mazadier, M.; Croucher, M.; Ollat, C.; Uzan, A.; Legrand, J.J.; Gueremy, C.; Le Fur, G. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—I: Anticonvulsant properties. *Eur. J. Pharmacol.* 1993, 34, 1–41. [CrossRef]

156. Debono, M.-W.; Le Guern, J.; Canton, T.; Doble, A.; Pradier, L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. *Eur. J. Pharmacol.* 1993, 235, 283–289. [CrossRef]

157. Fumagalli, E.; Funicello, M.; Rauen, T.; Gobbi, M.; Mannini, T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. *Eur. J. Pharmacol.* 2008, 578, 171–176. [CrossRef]

158. Kim, J.E.; Kim, D.S.; Kwak, S.E.; Choi, H.C.; Song, H.K.; Choi, S.Y.; Kwon, O.S.; Kim, Y.I.; Kang, T.C. Anti-glutamatergic effect of riluzole: Comparison with valproic acid. *Neuroscience* 2007, 147, 136–145. [CrossRef] [PubMed]

159. Rothan, H.A.; Amini, E.; Faraj, F.L.; Golpich, M.; Teoh, T.C.; Gholami, K.; Yusof, R. NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy. *Sci. Rep.* 2017, 7, 45540. [CrossRef] [PubMed]
163. Erickson, J.D. Functional identification of activity-regulated, high-affinity glutamine transport in hippocampal neurons inhibited by riluzole. *J. Neurochem.* **2017**, *142*, 29–40. [CrossRef] [PubMed]

164. Diao, L.; Hellier, J.L.; Uskert-Newson, J.; Williams, P.A.; Staley, K.J.; Yee, A.S. Diphenytoin, riluzole and lidocaine: Three sodium channel blockers, with different mechanisms of action, decrease hippocampal epileptiform activity. *Neuropharmacology* **2013**, *73*, 48–55. [CrossRef] [PubMed]

165. Minabe, Y.; Emori, K.; Shibata, R.; Kurachi, M. Antiepileptic effects of MK-801, a noncompetitive NMDA-receptor antagonist, in the low-frequency kindling model of epilepsy. *Jpn. J. Psychiatry Neurol.* **1992**, *46*, 755–761. [CrossRef]

166. Song, X.; Jensen, M.; Jogini, V.; Stein, R.A.; Lee, C.H.; McHaourab, H.S.; Shaw, D.E.; Gouaux, E. Mechanism of NMDA receptor channel block by MK-801 and memantine. *Nature 2018*, **556**, 515–519. [CrossRef]

167. Kovacic, P.; Somanathan, R. Clinical physiology and mechanism of dizocilpine (MK-801): Electron transfer, radicals, redox metabolism and motor impairment activity in vivo. *Neuropharmacology* **1995**, *34*, 1239–1258. [CrossRef]

168. Schultz, M.K.; Wright, L.K.M.; de Araujo Furtado, M.; Stone, M.F.; Moffett, M.C.; Kelley, N.R.; Bourne, A.R.; Lumeh, W.Z.; Schultz, M.; Nambiar, M.P. Development of a rat pilocarpine model of temporal lobe epilepsy. *Epilepsy Behav.* **2003**, *2015*, 38, 413–417. [CrossRef]

169. Sato, K.; Morimoto, E.; Okamoto, M. Anticonvulsant action of MK-801 in the kindling model of epilepsy. *Brain Res.* **1988**, *463*, 12–20. [CrossRef]

170. Kubova, H.; Mares, P. Effects of MK-801 (dizocilpine) and ketamine on strychnine-induced convulsions in rats: Comparison with benzodiazepines and standard anticonvulsants. *Physiol. Res. 1994*, **43**, 313–320.

171. Parsons, C.; Quack, G.; Bresink, I.; Baran, L.; Przegalinski, E.; Kostowski, W.; Krzascik, P.; Hartmann, S.; Danysz, W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. *Neuropharmacology* **1995**, *34*, 1239–1258. [CrossRef]

172. Nla, L.; Rukoiatjina, N.; Gorbunova, L.; Gmiro, V.; Magazanik, L. Role of NMDA and AMPA glutamate receptors in the mechanism of korazol-induced convulsions in mice. *Ross. Fiziol. Zhurnal Im. IM Sechenova* **2003**, 89, 292–301.

173. Brackett, R.L.; Pouv, B.; Blyden, J.F.; Nour, M.; Matsumoto, R.R. Prevention of cocaine-induced convulsions and lethality in mice: Effectiveness of targeting different sites on the NMDA receptor complex. *Neuropharmacology* **2000**, *39*, 407–418. [CrossRef]

174. Kulkarni, S.K.; Ticku, M.K. Interaction between GABAergic anticonvulsants and the NMDA receptor antagonist MK 801 against MES-and picrotoxin-induced convulsions in rats. *Life Sci.* **1989**, **44**, 1317–1323. [CrossRef]

175. O’Neill, S.K.; Bolger, G.T. Anticonvulsant activity of MK-801 and nimodipine alone and in combination against pentylenetetrazole and motor impairment activity in vivo. *Neuropharmacology* **1994**, *32*, 599–600. [CrossRef]

176. Vezzani, A.; Serafini, R.; Stasi, M.; Caccia, S.; Conti, I.; Tridico, R.; Samanieg, R. Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. *J. Pharmacol. Exp. Ther.* **1989**, **249**, 278–283.

177. Itzhak, Y.; Stein, I. Sensitization to the toxic effects of cocaine in mice is associated with the regulation of N-methyl-D-aspartate receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex. *Int. J. Neurpsychopharmacol.* **2009**, 12, 1395–1408. [CrossRef]

178. Niquet, J.; Lumley, L.; Baldwin, R.; Lyuboslavsky, P.; Almonte, A.; Murray, E.; Mosely, C.; Barber, J.; et al. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. *J. Physiol.* **2007**, *581*, 107–128. [CrossRef]

179. Thorat, S.; Kulkarni, S. Antagonism of caffeine-induced convulsions by ethanol and dizocilpine (MK-801) in mice. *Epilepsy Behav.* **2019**, 33, 347–374. [CrossRef]

180. Kreutzwieser, D.; Tawfic, Q.A. Expanding Role of NMDA Receptor Antagonists in the Management of Pain. *CNS Drugs* **2019**, *33*, 1063–1067. [CrossRef]

181. Weinbroum, A.A.; Ben-Abraham, R. Dextromethorphan and dexmedetomidine: New agents for the control of perioperative pain. *Eur. J. Surg.* **2003**, *167*, 563–569. [CrossRef]

182. Kimiskidis, V.K.; Mirtsou-Fidani, V.; Papaiasannidou, P.G.; Niopas, I.; Georgiadis, G.; Constadinidis, T.C.; Kazis, A.D. A phase I clinical trial of dextromethorphan in intractable partial epilepsy. *Methods Find. Exp. Clin. Pharmacol.* **1999**, **21**, 673–678. [CrossRef]
190. Smith-Hicks, C.L.; Gupta, S.; Ewen, J.B.; Hong, M.; Kratz, L.; Kelley, R.; Tierney, E.; Vaurio, R.; Bibat, G.; Sanyal, A.; et al. Randomized open-label trial of dextromethorphan in Rett syndrome. *Neurology* 2017, 89, 1684–1690. [CrossRef]

191. Hollander, D.; Pradas, J.; Kaplan, R.; McLeod, H.L.; Evans, W.E.; Munsat, T.L. High-dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies. *Ann. Neurol.* 1994, 36, 920–924. [CrossRef] [PubMed]

192. Majlesi, N.; Lee, D.C.; Ali, S.S. Dextromethorphan abuse masquerading as a recurrent seizure disorder. *Pediatr. Emerg. Care* 2011, 27, 210–211. [CrossRef] [PubMed]

193. Chenard, B.L.; Mennuti, F.S. Antagonists selective for NMDA receptors containing the NR2B subunit. *Curr. Pharm. Des.* 1999, 5, 381–404.

194. Pontecorvo, M.J.; Karbon, E.W.; Goode, S.; Clissold, D.B.; Borosky, S.A.; Patch, R.J.; Ferkany, J.W. Possible cerebroprotective and in vivo NMDA antagonist activities of sigma agents. *Brain Res. Bull.* 1991, 26, 461–465. [CrossRef]

195. Singh, L.; Oles, R.; Vass, C.; Woodruff, G. A slow intravenous infusion of N-methyl-DL-aspartate as a seizure model in the mouse. *J. Neurosci. Methods* 1991, 37, 227–232. [CrossRef]

196. Doyle, K.; Shaw, G. Investigation of the involvement of the N-methyl-D-aspartate receptor macrocomplex in the development of spermine-induced CNS excitation in vivo. *Br. J. Pharmacol.* 1996, 117, 1803. [CrossRef] [PubMed]

197. Tsuda, M.; Suzuki, T.; Misawa, M. Age-related decrease in the antiseizure effect of ifenprodil against pentylenetetrazole in mice. *Dev. Brain Res.* 1997, 104, 201–204. [CrossRef]

198. Mareš, P. Age and activation determines the anticonvulsant effect of ifenprodil in rats. *Naunyn Schmiedebergs Arch. Pharmacol.* 2014, 387, 753–761. [CrossRef]

199. Wang, X.; He, X.; Li, T.; Shu, Y.; Qi, S.; Luan, G. Anti-epileptic effect of ifenprodil on neocortical pyramidal neurons in patients with malformations of cortical development. *Exp. Ther. Med.* 2017, 14, 5757–5766. [CrossRef]

200. Zarnowski, T.; Kleinrok, Z.; Turski, W.; Czuczwar, S. The NMDA antagonist procyclidine, but not ifenprodil, enhances the therapeutic target against temporal lobe epilepsy. *Exp. Neurol.* 2022, 354, 114087. [CrossRef] [PubMed]

201. Maroso, M.; Balosso, S.; Ravizza, T.; Liu, J.; Aronica, E.; Iyer, A.M.; Rossetti, C.; Molteni, M.; Casalgrandi, M.; Manfredi, A.A. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. *Nat. Med.* 2010, 16, 413–419. [CrossRef]

202. Mareš, P. Age and activation determines the anticonvulsant effect of ifenprodil in rats. *Naunyn Schmiedebergs Arch. Pharmacol.* 2014, 387, 753–761. [CrossRef]

203. Maroso, M.; Balosso, S.; Ravizza, T.; Liu, J.; Aronica, E.; Iyer, A.M.; Rossetti, C.; Molteni, M.; Casalgrandi, M.; Manfredi, A.A. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. *Nat. Med.* 1997, 3, 97–1–12. [CrossRef] [PubMed]

204. Wang, X.; He, X.; Li, T.; Shu, Y.; Qi, S.; Luan, G. Anti-epileptic effect of ifenprodil on neocortical pyramidal neurons in patients with malformations of cortical development. *Exp. Ther. Med.* 2017, 14, 5757–5766. [CrossRef]

205. Gorlewicz, A.; Pijet, B.; Orlova, K.; Kaczmarek, L.; Knapska, E. Epileptiform GluN2B-driven excitation in hippocampus as a therapeutic target against temporal lobe epilepsy. *Exp. Neurol.* 2022, 354, 114087. [CrossRef] [PubMed]

206. Maroso, M.; Balosso, S.; Ravizza, T.; Liu, J.; Aronica, E.; Iyer, A.M.; Rossetti, C.; Molteni, M.; Casalgrandi, M.; Manfredi, A.A. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. *Nat. Med.* 2010, 16, 413–419. [CrossRef]

207. Zarnowski, T.; Kleinrok, Z.; Turski, W.; Czuczwar, S. The NMDA antagonist procyclidine, but not ifenprodil, enhances the protective efficacy of common antiepileptics against maximal electroshock-induced seizures in mice. *J. Neurotransm. Gen. Sect.* 1994, 97, 1–12. [CrossRef] [PubMed]

208. Gholizadeh, R.; Abdolmaleki, Z.; Bahremand, T.; Ghasemi, M.; Gharghabi, M.; Dehpour, A.R. Involvement of N-Methyl-D-Aspartate Receptors in the Anticonvulsive Effects of Licofelone on Pentylenetetrazole-Induced Clonic Seizure in Mice. *J. Epilepsy Res.* 2021, 11, 14–21. [CrossRef] [PubMed]

209. Hanson, J.E.; Ma, K.; Elstrott, J.; Weber, M.; Saillet, S.; Khan, A.S.; Simms, J.; Liu, B.; Kim, T.A.; Yu, G.-Q.; et al. GluN2A NMDA receptor enhancement improves brain oscillations, synchrony, and cognitive functions in Dravet Syndrome and Alzheimer’s Disease Models. *Cell Rep.* 2020, 30, 381–396.e4. [CrossRef] [PubMed]

210. Mareš, P.; Kozlová, L.; Mikulecká, A.; Kubová, H. The GluN2B-Selective Antagonist Ro 25-6981 Is Effective against PTZ-Induced Seizures and Safe for Further Development in Infantile Rats. *Pharmaceutics* 2021, 13, 1482. [CrossRef]

211. Mareš, P.; Tsenov, G.; Kubová, H. Anticonvulsant Action of GluN2A-Preferring Antagonist PEAQX in Developing Rats. *Pharmaceutics* 2021, 13, 415. [CrossRef]

212. Sveinbjörnsdóttir, S.; Sander, J.; Upton, D.; Thompson, P.; Patsalos, P.; Hirt, D.; Emre, M.; Lowe, D.; Duncan, J. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. *Epilepsy Res.* 1993, 16, 165–174. [CrossRef]

213. Lipton, S.A. Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. *NeuroRx* 2004, 1, 101–110. [CrossRef]

214. Comer, J.W.; Farber, N.B.; Jevtovic-Todorovic, V.; Selke, G.; Melson, A.K.; Hershey, T.; Craft, S.; Olney, J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. *Neuropsychopharmacology* 1999, 20, 106–118. [CrossRef]

215. Dikranian, K.; Tenkova, T.I.; Stefovska, V.; Turski, L.; Olney, J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. *Science* 1999, 283, 70–74. [CrossRef]

216. Johnston, M.V. Neurotransmitters and vulnerability of the developing brain. *Brain Dev.* 1995, 17, 301–306. [CrossRef]

217. Deutsch, S.J.; Mastroppoalo, J.; Rosse, R.B. Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. *Clin. Neuropharmacol.* 1998, 21, 320–332. [PubMed]

218. Mondadori, C.; Weiskrantz, L.; Buerki, H.; Petschke, F.; Fagg, G.E. NMDA receptor antagonists can enhance or impair learning performance in animals. *Exp. Brain Res.* 1989, 75, 449–456. [CrossRef] [PubMed]

219. Bye, C.M.; McDonald, R.J. A Specific Role of Hippocampal NMDA Receptors and Arc Protein in Rapid Encoding of Novel Environmental Representations and a More General Long-Term Consolidation Function. *Front. Behav. Neurosci.* 2019, 13, 8. [CrossRef]

220. Castellano, C.; Cestari, V.; Ciamei, A. NMDA receptors and learning and memory processes. *Curr. Drug Targets* 2001, 2, 273–283. [CrossRef]
216. Honey, G.D.; Honey, R.A.; O’Loughlin, C.; Sharar, S.R.; Kumaran, D.; Suckling, J.; Menon, D.K.; Sleator, C.; Bullmore, E.T.; Fletcher, P.C. Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: An fMRI study. *Cereb. Cortex* 2005, 15, 749–759. [CrossRef]

217. Hadj Tahar, A.; Blanchet, P.J.; Doyon, J. Motor-learning impairment by amantadine in healthy volunteers. *Neuropsychopharmacology* 2004, 29, 187–194. [CrossRef]

218. Rowland, L.M.; Astur, R.S.; Jung, R.E.; Bustillo, J.R.; Lauriello, J.; Yeo, R.A. Selective cognitive impairments associated with NMDA receptor blockade in humans. *Neuropsychopharmacology* 2005, 30, 633–639. [CrossRef]

219. Yaksh, T.L.; Tozier, N.; Horais, K.A.; Malkmus, S.; Rathbun, M.; LaFranco, L.; Eisenach, J. Toxicology Profile of N-Methyl-d-aspartate Antagonists Delivered by Intrathecal Infusion in the Canine Model. *Anesthesiology* 2008, 108, 938–949. [CrossRef]

220. Vranken, J.H.; Troost, D.; de Haan, P.; Pennings, F.A.; van der Vegt, M.H.; Dijkstra, M.G.; Hollmann, M.W. Severe toxic damage to the rabbit spinal cord after intrathecal administration of preservative-free S(+)-ketamine. *Anesthesiology* 2006, 105, 813–818. [CrossRef]

221. Gomes, L.M.; Garcia, J.B.; Ribamar, J.S., Jr.; Nascimento, A.G. Neurotoxicity of subarachnoid preservative-free S(+)-ketamine in dogs. *Pain Physician* 2011, 14, 83–90. [PubMed]

222. Karpinski, N.; Dunn, J.; Hansen, L.; Masliah, E. Subpial vacuolar myelopathy after intrathecal ketamine: Report of a case. *Pain* 1997, 73, 103–105. [CrossRef]